Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 2, 2012

Primary Completion Date

November 29, 2016

Study Completion Date

November 29, 2016

Conditions
Haemato-lymphoid Malignancies or Syndromes in Whom Allogeneic Stem Cell Transplantation is Warranted
Interventions
DRUG

total lymphoid irradiation and anti-thymocyte globulin

"* TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~* ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~* Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~* GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"

Trial Locations (4)

Unknown

Besançon University Hospital, Besançon

Lille University Hospital, Lille

Lyon University Hospital, Lyon

Nantes University Hospital, Nantes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT01566656 - Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies | Biotech Hunter | Biotech Hunter